Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux may leads to lower major bleeding compared with idraparinux (low certainty).
1 finding from 1 review
In‐hospital mortality · People undergoing elective abdominal aortic aneurysm repair
1 finding from 1 review
Operating time · People undergoing elective abdominal aortic aneurysm repair
1 finding from 1 review
Major complications ‐ lower limb ischaemia (up to 12 months) · People undergoing elective abdominal aortic aneurysm repair
Hand‐assisted laparoscopic repair showed no clear difference in major complications ‐ lower limb ischaemia (up to 12 months) compared with EVAR (low certainty).
1 finding from 1 review
Long‐term complications (12 months or longer if reported) · People undergoing elective abdominal aortic aneurysm repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality/survival (> 30 days) · People undergoing elective abdominal aortic aneurysm repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · People undergoing elective abdominal aortic aneurysm repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · People undergoing elective abdominal aortic aneurysm repair
1 finding from 1 review
Intervention not reported
Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Duration of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Severity scores · primary Raynaud's phenomenon
1 finding from 1 review
Intervention not reported
Patient preference scores · primary Raynaud's phenomenon
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review